NASDAQ: AUTLAutolus Therapeutics PLC Stock
$4.21-0.27 (-6.03%)
Updated Apr 24, 2024
AUTL Price
$4.21
Fair Value Price
$0.91
Market Cap
$1.12B
52 Week Low
$1.61
52 Week High
$7.45
P/E
-3.51x
P/B
10.04x
P/S
659.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.70M
Earnings
-$208.38M
Gross Margin
100%
Operating Margin
-9,619.26%
Profit Margin
-12,272.3%
Debt to Equity
2.37
Operating Cash Flow
-$146M
Beta
1.01
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AUTL Overview
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AUTL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AUTL ($4.21) is overvalued by 362.47% relative to our estimate of its Fair Value price of $0.91 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AUTL ($4.21) is not significantly undervalued (362.47%) relative to our estimate of its Fair Value price of $0.91 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AUTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AUTL due diligence checks available for Premium users.
Be the first to know about important AUTL news, forecast changes, insider trades & much more!
AUTL News
Valuation
AUTL fair value
Fair Value of AUTL stock based on Discounted Cash Flow (DCF)
Price
$4.21
Fair Value
$0.91
Overvalued by
362.47%
AUTL ($4.21) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AUTL ($4.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AUTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AUTL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.51x
Industry
15.69x
Market
41.27x
AUTL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.04x
Industry
5.86x
AUTL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AUTL's financial health
Profit margin
Revenue
$0.0
Net Income
-$77.2M
Profit Margin
0%
AUTL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AUTL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$375.4M
Liabilities
$263.9M
Debt to equity
2.37
AUTL's short-term assets ($275.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AUTL's short-term assets ($275.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AUTL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AUTL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.8M
Investing
-$1.5M
Financing
$23.0k
AUTL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AUTL vs Biotech Stocks
Autolus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.